Researchers Discover Important Piece of Genetic Aging Puzzle

Publication
Article
OncologyONCOLOGY Vol 11 No 10
Volume 11
Issue 10

A team of researchers has disrupted the natural progression of division and death in human cells, endowing the cells with an

A team of researchers has disrupted the natural progression of division and death in human cells, endowing the cells with an extended life-span.

Reporting in the journal Science, Brown University researchers describe how they can temporarily thwart the aging process by removing a gene, dubbed p21, from ordinary human cells cultivated in the laboratory. Cells without the gene divide for up to 30 additional generations before dying.

The researchers modified a gene “knock-out” method that is routinely used to genetically engineer mice for scientific research, and used the technology to remove the p21 gene from human cells. The knock-out method described in Science allows for specific changes in manipulating human cells.

“For obvious ethical and medical reasons, we can’t make a knock-out human, and we’re not going to clone a human, so this is as close as we can get,” said John Sedivy, associate professor of molecular biology, cellular biology and biochemistry. Because cancer cells appear to possess an infinite life-span, the finding may offer insight into how human cells become tumor cells, an important step in understanding the cancer process, he said.

Moreover, the finding has broad disease-fighting implications because it allows scientists to study genetically varied human cells without altering human beings to produce such cells.

The research may have important gene therapy implications. “There is no reason we couldn’t take cells from a patient, alter them, and put them back in that patient,” said Sedivy. 

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content